The Us Department Of Health And Human Services Has Awarded BioCryst Pharmaceuticals Up To A $69M Contract For The Procurement Of Up To 95,625 Doses Over A Five-year Period Of Rapivab (Peramivir Injection) For Influenza
Portfolio Pulse from Benzinga Newsdesk
The US Department of Health and Human Services has awarded BioCryst Pharmaceuticals a contract worth up to $69 million for the procurement of up to 95,625 doses of Rapivab over five years.
September 30, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharmaceuticals has been awarded a significant contract by the US Department of Health and Human Services, potentially worth up to $69 million over five years for Rapivab doses.
The contract with the US Department of Health and Human Services is a substantial revenue opportunity for BioCryst Pharmaceuticals, enhancing its financial outlook. The procurement of Rapivab doses indicates strong demand and government support, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100